Should NICE’s threshold range for cost per QALY be raised? No

NICE has recently raised the threshold for end of life drugs. Adrian Towse (doi:10.1136/bmj.b181) argues it should consider doing the same for other treatments, but James Raftery believes that the threshold is already too high

[1]  James Raftery,et al.  NICE and the challenge of cancer drugs , 2009, BMJ : British Medical Journal.

[2]  David Parkin,et al.  NICE's cost effectiveness threshold , 2007, BMJ : British Medical Journal.

[3]  Jane Wells,et al.  NICE appraisals should be everybody's business , 2007, BMJ : British Medical Journal.

[4]  Ann Barrett,et al.  How much will Herceptin really cost? , 2006, BMJ : British Medical Journal.

[5]  J Raftery,et al.  Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.

[6]  Joseph S. Pliskin,et al.  Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  S. Stearns,et al.  Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. , 2003, Health technology assessment.